Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2002
10/31/2002US20020159991 Modulation of Abeta levels by beta-secretase BACE2
10/31/2002US20020159981 A cell population cultured ex-vivo in a culture medium under conditions permitting cells of cell population to proliferate and at the same time reducing capacity of cells in utilizing copper, hence expanded yet not further differentiated
10/31/2002US20020159974 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002US20020159973 Administering to the patient at least one statin (HMG-Coa-reductase inhibitor) in an amount effective to modulate MHC class II (Major Histocompability complex) or CD/40(antigen) expression in the patient
10/31/2002US20020159951 Administering to the patient a contrast agent comprising, in an aqueous carrier, targeted vesicles formulated from a lipid or polymer, a prfluorocarbon gas, a targeting ligand, scanning the patient using ultrasound to obtain an image
10/31/2002DE10217066A1 Composition useful for treatment of central nervous system disorders, e.g. Alzheimer's disease comprises modulator of neuron-specific calcium sensor-1
10/31/2002DE10118452A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid
10/31/2002CA2791888A1 Proliposomal drug delivery system
10/31/2002CA2483507A1 Enzyme and snp marker for disease
10/31/2002CA2445888A1 Chiral, broad-spectrum antibacterial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation and compositions
10/31/2002CA2445508A1 Agent for topical ophthalmic treatment of ocular inflammatory diseases
10/31/2002CA2445197A1 T1r3 a novel taste receptor
10/31/2002CA2445179A1 Identification of essential genes of aspegillus fumigatus and methods of use
10/31/2002CA2444885A1 Methods and compositions for treating oral and esophageal lesions
10/31/2002CA2444691A1 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
10/31/2002CA2444675A1 Secreted proteins
10/31/2002CA2444570A1 Tricyclic compounds useful as hiv reverse transcriptase inhibitors
10/31/2002CA2444370A1 Use of radical scavenging compounds for treatment and prevention of no-dependent microcirculation disorders
10/31/2002CA2444347A1 Method for treating gout and binding uric acid
10/31/2002CA2444219A1 Antiangiogenic combination therapy for the treatment of cancer
10/31/2002CA2444028A1 Methods of treating syndrome x with aliphatic polyamines
10/31/2002CA2443937A1 Prostanoids augment ocular drug penetration
10/31/2002CA2443936A1 Use of ppar-alpha-gamma ligands or agonists to prevent the rupture of atherosclerotic plaques
10/31/2002CA2443935A1 Ppar-alpha-gamma ligands or agonists for the treatment of inflammation
10/31/2002CA2443560A1 Compositions and methods for reestablishing gene transcription through inhibition of dna methylation and histone deacetylase
10/31/2002CA2443373A1 New polynucleotides and polypeptides of the erythropoietin gene
10/31/2002CA2442591A1 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
10/31/2002CA2439693A1 Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof
10/30/2002EP1252894A1 Use of agt and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions
10/30/2002EP1252883A1 Process for reducing partially or completely the symptoms associated with the histamin release within the human body
10/30/2002EP1252882A1 Process to increase the threshold tolerance of the sensitive skin
10/30/2002EP1252519A2 Methods for detecting cancer of the central nervous system
10/30/2002EP1252333A2 Methods and materials relating to cd84-like polypeptides and polynucleotides
10/30/2002EP1252330A2 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
10/30/2002EP1252313A2 Use of dendroaspin as a vehicle for non-dendroaspin domains
10/30/2002EP1252309A2 Mhc class ii restricted t cell epitopes from the cancer antigen ny-eso-1
10/30/2002EP1252308A2 Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
10/30/2002EP1252300A2 Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
10/30/2002EP1252298A2 Phosphodiesterases
10/30/2002EP1252189A2 Novel human nucleic acid molecules and polypeptides encoding cation channels
10/30/2002EP1252188A2 G-protein coupled receptors
10/30/2002EP1252179A2 High purity lipopeptides, lipopeptide micelles, processes for preparing same and pharmaceutical compositions containing them
10/30/2002EP1252175A1 Antisense modulation of survivin expression
10/30/2002EP1252162A1 Alpha v integrin receptor antagonists
10/30/2002EP1252158A1 Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
10/30/2002EP1252157A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
10/30/2002EP1251873A1 Antagonist of th-1 immuneresponse inducing cytokine for the treatment of autoimmune diseases
10/30/2002EP1251872A1 Compositions and methods for treating cell proliferation disorders
10/30/2002EP1251868A1 Combination therapy for the treatment of inflammatory and respiratory diseases
10/30/2002EP1251864A1 Pharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
10/30/2002EP1251862A1 Ophthalmic compositions for treating ocular hypertension
10/30/2002EP1251859A1 Novel compounds
10/30/2002EP1251857A1 Pharmaceutical parenteral composition containing a bisphosphonate
10/30/2002EP1251855A1 Selective estrogen receptor modulators in combination with estrogens
10/30/2002EP1251851A1 Treating allergic and inflammatory conditions
10/30/2002EP1251850A2 Combination therapy for cancer
10/30/2002EP1251843A1 Compositions for delivery of a cortisol antagonist
10/30/2002EP1251840A2 Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
10/30/2002EP1251839A2 Use of cox-2 inhibitors for the treatment of constipation
10/30/2002EP1251836A2 Use of bvdu for inhibiting the growth of hyperproliferative cells
10/30/2002EP1251830A1 Continuous method for preparing pharmaceutical granules
10/30/2002EP1251829A1 Electrospun pharmaceutical compositions
10/30/2002EP1152731A4 A skin care composition that mediates cell to cell communication
10/30/2002EP1140973A4 Protein-protein interactions in neurodegenerative disorders
10/30/2002EP1135193B1 Agents provided for treating tumors, based on liposomes, and containing tamoxifen
10/30/2002EP1061925B1 Combination of a gaba-a alpha 5 inverse agonist and a nicotinic agonist
10/30/2002EP1017412A4 Genes coding proteins for early liver development and their use in diagnosing and treating liver disease
10/30/2002EP1011634B1 Preparation of pharmaceutical compositions
10/30/2002EP0695187B1 Inhibition, control and regression of angiogenesis with hyaluronic acid or hyaluronic acid and nsaid
10/30/2002CN1377424A Methods of reparing tandemly repeated DNA sequences and extending cell life-span using nuclear transfer
10/30/2002CN1377405A Personal care articles
10/30/2002CN1377355A Amino substituted pyrazolo [1,5-2]-1,5-pyrimidines and pyrazolo [1,5-2]-1,3, 5-triazines
10/30/2002CN1377354A Certain alkylene diamine-substituted pyrazolo [1,5-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines
10/30/2002CN1377282A Fatty acid-anticancer conjugates and uses thereof
10/30/2002CN1377280A Diagnosis and treatment of neuroectodermal tumors
10/30/2002CN1377278A Prevention and treatment of amyloidogenic disease
10/30/2002CN1377277A Use of leptin in inhibition of endothelial cell proliferation
10/30/2002CN1377275A Peptides that block viral infectivity and methods of use thereof
10/30/2002CN1377272A Agents for intravitreal administration to treat or prevent disorders of the eye
10/30/2002CN1377269A Vitronectin receptor antagonists
10/30/2002CN1377267A Retard form containing 2-lipoic acid (derivatives)
10/30/2002CN1377265A Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients
10/30/2002CN1377264A Method for treating endometriosis or infertility, or improving fertility
10/30/2002CN1377262A Method and composition for prophylaxis and treatment of symptoms associated with cold and influenza-like illnesses
10/30/2002CN1377260A Methods and compounds for inhibiting amyloid deposits
10/30/2002CN1376469A Slow release antibiotics preparation of bioactive substance
10/30/2002CN1376459A Preparation method for antibiotics composition
10/30/2002CN1093399C Small particle liposome aerosols for delivery of anti-cancer drugs
10/30/2002CA2383469A1 Treatment of t-cell mediated diseases
10/29/2002US6472529 Viricides
10/29/2002US6472434 Vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives,
10/29/2002US6472433 Administering in an animal a dose of atleast 2.5 milligrams of an enantimerically pure r-nonsteroidal anti-inflammatory drugs per kilogram of the animal's body weight for the treatment of inflammation
10/29/2002US6472432 Treatment of rosacea using lipoic acid
10/29/2002US6472423 Pharmaceutical composition
10/29/2002US6472421 Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
10/29/2002US6472420 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
10/29/2002US6472406 Sulfonamidomethyl phosphonate inhibitors of beta-lactamase
10/29/2002US6472403 αV integrin receptor antagonists
10/29/2002US6472401 Administering an antiallergen of loratadine or metabolite of loratadine, desloratadine; migraines, stroke, orthostatic hypotension, gastrointestinal stasis, nausea, dizziness and jet lag; also psychological disorders; 5-ht7 receptors
10/29/2002US6472398 Spiropiperidine derivatives as melanocortin receptor agonists
1 ... 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 ... 1151